Perry Gregory D
SEC-identified person · CIK 1236371 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Merus N.V. MRUS | Director · Chief Financial Officer & PFO | filed 2020–2025 |
| Kala Pharmaceuticals, Inc. KALA | Director | filed 2018–2025 |
| Finch Therapeutics Group, Inc. FNCH | Chief Financial Officer | filed 2021–2022 |
| QLT INC/BC QLTI | See Remarks | filed 2016–2017 |
| Aegerion Pharmaceuticals, Inc. AEGR | See Remarks | filed 2015–2016 |
| Ocata Therapeutics, Inc. OTCBB:ACTC | Director | filed 2012–2016 |
| Sesen Bio, Inc. SESN | Chief Financial and Business | filed 2014–2015 |
| Invivo Therapeutics Holdings Corp. None | Interim CFO | filed 2013–2014 |
| Immunogen, Inc. IMGN | Chief Financial Officer | filed 2009–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.